Two decades of data reveal overall increase in pain, opioid use among U.S. adults
Prompted by a call from the National Academy of Medicine, then the Institute of Medicine, for improved national data on […]
(HealthDay)—Many drugs—both prescription and over-the-counter—can cause side effects like dizziness or upset stomach. But some can affect you in surprising […] A law meant to shame doctors who receive payments and gifts from drug companies in exchange for prescribing their medications […] Heart disease patients prescribed opioids at hospital discharge were less likely to follow up with their healthcare provider or to […] Despite the jackhammerlike rhythm of a mechanical ventilator, Alicia Moreno had dozed off in a chair by her 1-year-old’s hospital […] DUBLIN–(BUSINESS WIRE)–Dec. 27, 2018– Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved […] NEW YORK, December 21, 2018 (GLOBE NEWSWIRE) – Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and […] BOSTON, Dec. 13, 2018 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization […] NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development […] NEWTON, Mass, Dec. 01, 2018 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line […]Medications
Everyday medications that can ruin your sex life
Are disclosure laws the cure for conflicts created by pharma payments to physicians?
Heart patients prescribed opioids at hospital discharge often fare worse
When medicine makes patients sicker
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns
FDA Approves Elzonris (tagraxofusp-erzs), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy
Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting